SAN DIEGO and PENNINGTON, N.J., Nov.
29, 2018 /PRNewswire/ -- OncoSec Medical Incorporated
(OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer
immunotherapies, announced today the presentation of new data from
the company's Phase 2 study of TAVO™ (tavokinogene telseplasmid)
for the treatment of metastatic melanoma. The newly presented data
reports abscopal responses with TAVO™ monotherapy, finding that
treatment with TAVO™ monotherapy resulted in 47 percent of patients
experiencing tumor regression in at least one untreated lesion.
These data were selected for an oral presentation at Melanoma
Bridge 2018, taking place November 30 to
December 1, Naples,
Italy.
"These findings are significant because they clearly demonstrate
that intratumoral treatment with TAVO is having a systemic effect
that goes beyond the treated tumor, and to see that effect in
nearly half of treated patients is remarkable, particularly with
such a well-tolerated therapy," said Alain
Algazi, M.D., Lead Trial Investigator, Associate Professor,
Department of Medicine (Hematology/Oncology), at the University of California San Francisco (UCSF) Helen
Diller Family Comprehensive Cancer Center and Strategic Clinical
Advisor to OncoSec. "These findings build upon our previous report
from this study showing an approximate 30 percent overall response
rate with monotherapy TAVO and further support the potential value
of TAVO therapy for this patient population."
OMS-100 is a Phase 2 study of monotherapy TAVO for the treatment
of patients with metastatic melanoma. In all, 51 subjects were
enrolled in three treatment arms. Reponses data from the study were
previously reported, with approximately 30 percent of subjects
achieving a best overall response based on RECIST criteria. In
addition, 47 percent of patients had stable disease, resulting in a
DCR (Disease Control Rate) of 77 percent. Among patients who
responded to monotherapy, investigators noted upregulation of
innate immune mediators in the periphery of responding patients
after treatment. TAVO was well tolerated, with predominantly grade
1 procedural related adverse events.
Slides from the Melanoma Bridge will be available following the
conference on www.oncosec.com.
About OncoSec Medical Incorporated
OncoSec is a
clinical-stage biotechnology company focused on developing
cytokine-based intratumoral immunotherapies to stimulate the body's
immune system to target and attack cancer. OncoSec's lead
immunotherapy platform – TAVO™ (tavokinogene telseplasmid) –
enables the intratumoral delivery of DNA-based interleukin-12
(IL-12), a naturally occurring protein with immune-stimulating
functions. The technology, which employs electroporation, is
designed to produce a controlled, localized expression of IL-12 in
the tumor microenvironment, enabling the immune system to target
and attack tumors throughout the body. OncoSec has built a
deep and diverse clinical pipeline utilizing TAVO™ as a potential
treatment for multiple cancer indications either as a monotherapy
or in combination with leading checkpoint inhibitors; with the
latter potentially enabling OncoSec to address a great unmet
medical need in oncology: anti-PD-1 non-responders. Results
from recently completed clinical studies of TAVO™ have demonstrated
a local immune response, and subsequently, a systemic effect as
either a monotherapy or combination treatment approach. In
addition to TAVO™, OncoSec is identifying and developing new
DNA-encoded therapeutic candidates and tumor indications for use
with its ImmunoPulse® platform. For more information, please
visit www.oncosec.com.
ImmunoPulse® is a registered trademark of OncoSec Medical
Incorporated, San Diego, CA,
USA.
Forward-Looking Statements
This press release
contains "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by words such as
"can," "may," "will," "suggest," "look forward to," "potential,"
"understand," and similar references to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on
management's current preliminary expectations and are subject to
risks and uncertainties, which may cause our results to differ
materially and adversely from the statements contained herein.
Potential risks and uncertainties that could cause actual results
to differ from those predicted include, among others, the
following: uncertainties inherent in pre-clinical studies and
clinical trials, such as the ability to enroll patients in clinical
trials and the risk of adverse events; unexpected new data, safety
and technical issues; our ability to raise additional funding
necessary to fund continued operations; and the other factors
discussed in OncoSec's filings with the Securities and Exchange
Commission.
Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
disclaims any obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
CONTACT
Investor Relations:
Stern Investor Relations
Will O'Connor
Phone: (212) 362-1200
will@sternir.com
Media Relations:
Michael Lampe
Scient Public Relations, Inc.
(484) 575-5040
michael@scientpr.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/oncosec-presents-new-data-during-oral-presentation-at-melanoma-bridge-demonstrating-intratumoral-monotherapy-tavo-induces-abscopal-responses-in-metastatic-melanoma-patients-300757580.html
SOURCE OncoSec Medical Incorporated